One in 10 Babies are Born Too Soon
With an incidence of one in ten pregnancies1, preterm birth is considered by many medical experts to be a public health crisis. The emotional, financial, and long-term health implications for preterm babies and their families can be overwhelming. Up until this point, ways to accurately predict the risk of a preterm delivery have been limited, with only a small percentage of high risk patients identified through clinical or demographic risk factors.
Determine Your Patient’s Risk of Spontaneous Preterm Birth, Even if She Lacks Obvious Risk Factors
The PreTRM® Test provides physicians with their patients’ risk for spontaneous premature birth in asymptomatic singleton pregnancies. This pivotal information — provided in the form of an individual risk percentage — gives you sufficient time and vital insights to make informed treatment decisions with your patients.
PreTRM® accurately identifies more patients at higher risk of spontaneous preterm birth than traditional methods alone
Accurately identifying women at higher risk for spontaneous preterm delivery is a critical first step to addressing an early delivery’s health impacts.
The PreTRM Test is Suitable for 88% of Singleton Pregnant Women4,6
PreTRM® Intended Use:
The PreTRM® Test for Risk Management predicts the risk of spontaneous preterm birth (before 37 weeks) in asymptomatic women (no signs or symptoms of preterm labor, with intact membranes) ≥18 years old with a singleton pregnancy. The PreTRM Test is performed via a single blood draw between 19wk/1d-20wk/6d (134-146 days) gestation. It is not intended for use in women who have a multiple pregnancy, have a known or suspected fetal anomaly, or are on any form of progesterone therapy after the first trimester.
- Women ≥18 years old with a singleton pregnancy
- Not on heparin therapy
- No prior history of preterm birth or shortened cervix
- Asymptomatic for preterm labor
- Not on progesterone therapy after the first trimester
- No known or suspected fetal anomaly
Offer the PreTRM® Test at Your Practice
- Hamilton BE, et al. Births: Provisional data for 2020. Vital Statistics Rapid Release; no 12. Hyattsville, MD: National Center for Health Statistics. May 2021.
- Iams, JD. Clinical Practice. Prevention of preterm parturition. N Engl J Med. 2014;370:254-61.
- Saade GR, et al. Development and validation of a spontaneous preterm delivery predictor in asymptomatic women. Am J Obstet Gynecol. 2016;214:633.e1-24.
- Petrini JR, et al. Estimated effect of 17 alpha-hydroxyprogesterone caproate on preterm birth in the United States. Obstet Gynecol. 2005;105:267-72.
- Martin JA, et al. Births: Final Data for 2002. Natl Vital Stat Rep. 2003; 52(10):1-113.
- Hassan SS, et al. Vaginal progesterone reduces the rate of preterm birth in women with a sonographic short cervix: a multicenter, randomized, double-blind, placebo-controlled trial. Ultrasound Obstet Gynecol. 2011;38:18-31.
- Martin JA, et al. Births: Final Data for 2009. Natl Vital Stat Rep. 2011; 60(1):1-70.